ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Atlanta, GA, USA:

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: ADX-914

Phase 2

Q32 Bio

Sandy Springs, Georgia, United States and 26 other locations

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: GHZ339

Phase 2

Novartis
Novartis

Atlanta, Georgia, United States and 47 other locations

Locations recently updated

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema ...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

Phase 4

Lilly
Lilly

Atlanta, Georgia, United States and 74 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Sandy Springs, Georgia, United States and 83 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Johns Creek, Georgia, United States and 540 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Sandy Springs, Georgia, United States and 556 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Sandy Springs, Georgia, United States and 194 other locations

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Active, not recruiting
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

Phase 2

Nektar Therapeutics
Nektar Therapeutics

Marietta, Georgia, United States and 118 other locations

Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

Phase 3

AbbVie
AbbVie

Dawsonville, Georgia, United States of America and 97 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

Stockbridge, Georgia, United States and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems